Arlegui, Hugo
Bollaerts, Kaatje
Bauchau, Vincent
Nachbaur, Gaëlle
Bégaud, Bernard
Praet, Nicolas
Article History
First Online: 12 September 2020
Declarations
:
: This study is part of a PhD programme funded by GlaxoSmithKline Biologicals SA and the ANRT (Association Nationale pour la Recherche et la Technologie, Paris, France).
: Hugo Arlegui was employed by the GSK group of companies at the time of the study, in the framework of a PhD programme. Vincent Bauchau, Gaëlle Nachbaur and Nicolas Praet are employed by the GSK group of companies. Vincent Bauchau, Gaëlle Nachbaur and Nicolas Praet also hold shares in the GSK group of companies. Kaatje Bollaerts and Bernard Bégaud have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: All authors attest they meet the ICMJE criteria for authorship. All authors were involved in the conception of the study. Hugo Arlegui participated in the collection and generation of the study data. Hugo Arlegui performed the study. All authors were involved in the analyses and interpretation of the data. All authors revised the manuscript critically for important intellectual content and gave final approval to submit for publication.